Insugen 30/70 Solution for Injection 40 IU/ml is a premixed insulin formulation containing 70% Insulin Isophane (NPH insulin) and 30% Human Insulin, designed for the management of diabetes mellitus requiring insulin therapy. This biphasic insulin preparation offers both intermediate-acting and short-acting components, providing basal glycemic control along with prandial glucose regulation. The intermediate-acting Insulin Isophane component ensures prolonged insulin activity, helping to maintain basal insulin levels, while the human insulin fraction facilitates rapid onset of action to manage postprandial glucose excursions. Insugen 30/70 is indicated for adult and pediatric patients with type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not provide adequate glycemic control. The solution is administered subcutaneously, with dosing individualized based on patient requirements, blood glucose monitoring, and glycemic targets. Proper injection technique and rotation of injection sites are recommended to minimize lipodystrophy. Hypoglycemia is the most common adverse effect and patients should be educated on its recognition and management. Insugen 30/70 should be stored under recommended conditions to maintain potency. This insulin preparation is a vital component in comprehensive diabetes management aimed at achieving optimal glycemic control and reducing the risk of diabetes-related complications.